Exclusion from prescription according to § 92 (1) SGB V
The G-BA may restrict or exclude the prescription of drugs according to §92 SGB V, if the inappropriateness has been proven or if another, more economical treatment option with comparable diagnostic or therapeutic benefit is available.
Log in to read more ...
The AMNOG monitor is a subscription-based service for pharmaceutical manufacturers and institutions. Enter your account details here in order to analyse the results of the early benefit assessment in Germany – or contact us for more information.